IR BioSciences Holdings Inc., through its wholly owned subsidiary ImmuneRegen BioSciences, Inc., is developing Homspera™ and its derivatives Radilex™ and Viprovex™ as a family of countermeasures for multiple homeland security threats, including chemical agents, Acute Radiation Sickness (ARS) from a dirty bomb or nuclear disaster, and infectious disease/biological warfare scenarios. This positions the base compound Homspera as a potential Universal Protectant. Homspera is derived from modified homeostatic Substance P, a naturally occurring neuropeptide immunomodulator and homeostatic compound with the dual effect of improving pulmonary function and the stimulation of the human immune system. Further advances with the Office of Naval Research (ONR) and the U.S. Air Force are currently being pursued.
Press Release Source: ImmuneRegen BioSciences, Inc.
ImmuneRegen Announces Further Results From Anthrax Treatment Study
Thursday August 17, 7:00 am ET
Hyperion Biotechnology, Inc. and ImmuneRegen Continue Testing the Effects of Viprovex(TM) for Possible Use to Treat the Effects of Anthrax Exposure
SCOTTSDALE, Ariz., Aug. 17 /PRNewswire-FirstCall/ -- ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBO - News), today announced further results from pre-clinical tests of Viprovex(TM) for possible use to treat the effects of pulmonary anthrax infection. ImmuneRegen is collaborating with Hyperion Biotechnology Inc. to perform these tests at Hyperion's research facility located on the United States Air Force School of Aerospace Medicine (USAFSAM) campus in Brooks City-Base, Texas.
Initial studies in a well-established mouse model system indicate a potential positive effect in the use of Viprovex to both prophylactically and therapeutically treat the effects of a near lethal anthrax-exposure. Animals exposed to near lethal doses of anthrax spores were treated with Viprovex either before anthrax exposure or afterwards and test results indicated a survival rate ranging from 20% to 70% of control animals that otherwise would likely have died. In vitro studies confirm elevation of multiple classes of immunomodulators in response to Viprovex, and management believes these results add further support to continued efforts towards additional testing of Viprovex. "The company is optimistic in its development of the compound for this unmet medical need," says a company spokesperson.
Studies utilizing a formulation of the same active ingredient, Homspera(TM), in an animal model of lethal radiation exposure, show increased survival and immune system reconstitution, lending credence to the hypothesis that Homspera may be of value in a number of biodefense applications.
Viprovex is the trade name used in referring to formulations of Homspera for potential indications for treatment of maladies caused by exposure to various chemical and biological agents. Homspera is a generic name used by the Company to describe the synthetic peptide Sar9, Met (O2)11-Substance P. Sar9, Met (O2)11-Substance P is an analog of the naturally occurring human neuropeptide Substance P, which can be found throughout the body, including in the airways of humans and many other species. All of the Company's research and development efforts are early, pre-clinical stage and both Homspera and Viprovex have only undergone exploratory studies to evaluate their biological activity in small animals.
Hyperion Biotechnology was founded in 1998 and has active programs in the area of biomarker discovery, wound healing, performance enhancement, infectious disease treatment and other homeland security related topics. These research efforts have been funded by contracts with the Department of Defense (DoD).
The development of Homspera and its derivatives is pursuant to the U.S. Food and Drug Administration's "animal efficacy" rule, which allows an expedited development and approval process. In addition, these compounds are candidates for the Strategic National Stockpile under current BioShield law.
The majority of our current development efforts are aimed at developing two possible therapeutic applications for Homspera: Radilex and Viprovex. Radilex is being developed as a formulation of Homspera intended to treat acute radiation exposure. Viprovex is being developed for the treatment of maladies caused by exposure to chemical and biological weapons agents.
ImmuneRegen BioSciences is currently pursuing FDA approval for Radilex and Viprovex, but both are still experimental drug candidates, and are not yet approved for human use.
For more information, please visit the company's website at http://www.immuneregen.com/.